This week, 11 biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Stemline Therapeutics, Inc. (STML) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. For more information, get Portfolio Grader’s complete analysis of STML stock.
Pharmacyclics, Inc. (PCYC) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.
Acorda Therapeutics, Inc. (ACOR) improves from a C to a B rating this week. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
This is a strong week for Northwest Biotherapeutics, Inc. (NWBO). The company’s rating climbs to B from the previous week’s C. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.
Agios Pharmaceuticals, Inc.’s (AGIO) ratings are looking better this week, moving up to an A from last week’s B. For more information, get Portfolio Grader’s complete analysis of AGIO stock.
MediciNova, Inc. (MNOV) earns an A this week, jumping up from last week’s grade of B. Medicinova acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.
The rating of BioMarin Pharmaceutical (BMRN) moves up this week, rising from a C to a B. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.
This week, Seattle Genetics, Inc.’s (SGEN) ratings are up from a C last week to a B. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.
Ambit Biosciences Corp. (AMBI) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of AMBI stock.
Paratek Pharmaceuticals Inc (PRTK) boosts its rating from a C to a B this week. Shares of the stock have been changing hands at an unusually rapid pace, up 988.8% from the week prior. For more information, get Portfolio Grader’s complete analysis of PRTK stock.
Amgen’s (AMGN) ratings are looking better this week, moving up to an A from last week’s B. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. The stock has a dividend yield of 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
